RT Journal Article
T1 Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
A1 Ribelles, Nuria
A1 Pérez-Villa, Lidia
A1 Jerez, José Manuel
A1 Pajares, Bella
A1 Vicioso, Luis
A1 Jiménez, Begoña
A1 Luque, Vanessa de
A1 Franco, Leonardo
A1 Gallego, Elena
A1 Márquez, Antonia
A1 Álvarez, Martina
A1 Sánchez-Muñoz, Alfonso
A1 Pérez-Rivas, Luis
A1 Alba, Emilio
K1 Neoplasias de la Mama
K1 Antineoplásicos
K1 Queratina-5
K1 Queratina-6
K1 Receptor del Factor de Crecimiento Epidérmico
K1 Neoplasias Hormono-Dependientes
K1 Factor de Crecimiento Epidérmico
K1 Mastectomía
K1 Receptores de Progesterona
K1 Receptores Estrogénicos
K1 Antígeno Ki-67
AB INTRODUCTIONRecurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes.METHODSExpression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER-, PR-, HER2-, any Ki-67). Subtype definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14, any CK 5/6, any EGFR), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER-, PR-, HER2+, any Ki-67, any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER-, PR-, HER2-, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER-, PR-, HER2-, any Ki-67, CK 5/6-, EGFR-). Each four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value.RESULTSLuminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months.CONCLUSIONSEach intrinsic subtype has a particular pattern of relapses over time which change depending on the level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients.
PB BioMed Central
SN 1465-5411
YR 2013
FD 2013-10-22
LK http://hdl.handle.net/10668/1519
UL http://hdl.handle.net/10668/1519
LA en
NO Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res. 2013; 15(5):R98
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 5, 2025